You are now searching

   

New York BBB Wise Giving Report for
Drugs for Neglected Diseases Initiative, North America

A BBB Accredited charity

 



Expiration Date:
06/2015
Name:
Drugs for Neglected Diseases Initiative, North America
Formerly known as:
--
Address:
40 Wall Street, 24th Floor
New York, NY 10005
Phone:
646-616-8680
Web Site:
Year, State Incorporated:
2007, Delaware
Affiliates:
-- Also know as: DNDi North America
Stated Purpose:
" To develop new drugs, or new formulations of existing drugs for patients suffering from the most communicable diseases. And bridging existing R&D gaps in essential drugs for these disease by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other partners. "





Evaluation Conclusions
 

              
Drugs for Neglected Diseases Initiative, North America (DNDi North America) meets the 20 Standards for Charity Accountability.




Programs
 

              
DNDi's primary objective is to deliver a total of 11 to 13 new treatments by 2018 for the diseases that include Human African Trypanosomiasis (HAT); Visceral leishmaniasis(VL); American trypanosomiasis; Helminth infections; Pediatric HIV; Malaria. DNDi's secondary objectives are to utilize and strengthen existing research capacity in disease-endemic countries by training scientists and health workers and equipping labs and clinics and to raise awareness about the urgent need to develop new drugs for neglected diseases and advocate for increased public responsibility.



Governance
 

              
Chief Executive Officer:
Rachel M. Cohen, Executive Director
Compensation*:
$167,468
Chair of the Board:
Bennett Shapiro
Chair's Profession / Business Affiliation:
PureTech Ventures
Board Size:
7
Paid Staff Size:
5



*Compensation includes annual salary and, if applicable, benefit plans, expense accounts, and other allowances.




Fund Raising
 

              
Method(s) Used:


Direct mail appeals, invitations to fund raising events, grant proposals, internet
Fundraising costs were 5.6% of related contributions. (Related contributions, which totaled $2,357,755, are donations received as a result of fund raising activities.)




Tax Status
 

              
This organization is tax-exempt under section 501(c)(3) of the Internal Revenue Code. It is eligible to receive contributions deductible as charitable donations for federal income tax purposes.




Financial
 

              
The following information is based on DNDi North America's Audited Financial Statements for the fiscal year ended December 31, 2012.

Source of Funds  

Contributions

$1,499,245

Seeding Funding-DNDi

823,010

Foundations

15,500

Corporate

10,000

Contributed Services

10,000

Interest income

235

Total Income

$2,357,990

Program Expenses  

Grants to R&D

$1,544,012

Raising Awareness to R&D

687,429
Total Program Expenses:
Fund Raising Expenses
Administrative Expenses

Total expenses

Expenses in Excess of Income

2,231,441
131,112
82,445

$2,444,998

$(87,008)




Uses of Funds as a % of Total Expenses


Programs: 91%  Fund Raising: 5%  Administrative 3% 
Roll the cursor over the pie chart to see the dollar amounts.


Beginning net assets $150,141
Ending net assets 53,132
Total liabilities 69,002

Total assets

$122,134






 

A copy of this report has been shared with the organization prior to publication. It is not intended to recommend or deprecate, and is furnished solely to assist you in exercising your own judgment. The name Better Business Bureau is a registered service mark of the Council of Better Business Bureaus, Inc.

This report is not to be used for fundraising or promotional purposes and may not be reproduced or distributed in whole or in part.